Liver Heart Articles & Analysis
23 news found
Through this partnership, we aim to provide researchers with the tools and expertise needed to accelerate their research efforts in developing liver models for drug discovery, accurate cancer models for precision medicine, and exploring the potential of combining light and extrusion bioprinting modalities to advance tissue ...
ByCELLINK
P000912-LYSK1-A.0 Soft tissue homogenizing CK14 The CK14 kit is the perfect solution for soft tissue homogenization, like brain, liver, kidney, skin, plant leaves, mammalian cells and more. Compatible with Precellys Evolution Touch, Precellys 24 Touch and Minilys, the kit comes in different sizes, including 0.5mL, 2mL, 2mL Protein Safe or 7mL standard tubes. ...
The second, REVeRT (REconstitution Via mRNA Trans-splicing) technology platform, allows efficient reconstitution of large genes (>5Kb) in various tissues such as retina, brain, heart, liver, and skeletal muscle. The third, AAV Transactivation is a CRISPR-Cas–based AAV gene therapy platform that enables to regulate one or multiple genes in vivo. ...
Depending on the country, Ultravist is approved for use across a vast range of indications such as CT of the head, chest, heart, abdomen, and liver; multi-detector CT for stroke/ischemic damage and imaging of the abdominal viscera; CT angiography of vessels in the head, heart and peripheral parts of the body; conventional radiology for duct ...
ByBayer AG
Difficulty breathing: During sedation heart rate can slow, and breathing can become difficult, though this is rare and easily treated with oxygen by your nurse. ...
Radiopharmaceuticals are radioactive agents that are utilized for the diagnosis of infection, vessel-related diseases, bone/bone marrow diseases, tumors, and other diseases in heart, lung, kidney, liver etc. Using larger amount of radiation, some radiopharmaceuticals can be used to treat cancers by destroying the affected tissues. ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde as an independent Non-Executive Director of the Company. ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a secured loan facility agreement of EUR 10 million with Kreos Capital VI (UK) Limited (“Kreos”). ...
DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company. ...
In combination with work continuing at the University of Miami, we believe that our ImmCelz® platform has enormous potential to improve outcomes for patients across multiple indications, including Stroke, Type I Diabetes, Heart Disease, Liver Disease, and Kidney Disease." Human iPSc's are genetically reprogrammed to differentiate into a wide array of human ...
Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that all proposed resolutions submitted to the Annual and Extraordinary General Meeting of Shareholders were approved ...
Reporting of primary endpoint on track for Q4 2022 FDA regulatory submission on track for mid-2023 70% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably to published literature in this high-risk patient population Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment ...
We believe that our Immcelz® program has enormous potential to improve outcomes for patients across multiple indications, including stroke, Type I diabetes, heart disease, liver disease, and kidney disease." About ImmCelz ImmCelz®, which is protected by trade secrets and published U.S. patents, utilizes adult stem cells derived from qualified donors to ...
Upon successful approval to proceed with clinical trials for stroke, the Company anticipates accelerating additional therapies under the ImmCelz® umbrella, including for type I diabetes, heart disease, liver disease, and kidney disease. About Creative Medical Technology Holdings Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology ...
It is mainly concentrated in the organs of the human body that have a high workload and require sufficient energy to function properly, such as the heart, brain, and liver. The content of coenzyme Q10 in the human body reaches its peak at the age of 20, after which the ability to synthesize coenzyme Q10 by itself begins to decline. ...
Spare parts for the people who need them: Lungs, livers, kidneys, hearts. It’s been nearly five years since Kamen announced the launch of BioFabUSA, a program of the Advanced Regenerative Manufacturing Institute to jump-start the large-scale production of synthetic human tissue. ...
As a small molecule, HST5040 has the ability to distribute to all affected tissues and thus has the potential to be active throughout the body, including the liver, kidneys, brain, heart and muscles. HST5040 is designed for convenient daily administration at home as a liquid formulation taken either orally or through a gastric feeding tube. ...
On May 31, 2021, Mr. Dominic Barton, Canadian Ambassador to China, accompanied by Consul General Jeff David and trade commissioners from the Canadian Consulate General in Chongqing, visited SWS ...
As a result of longer life expectancy and the incidence of major pathologies such as cancer and diabetes, the number of people waiting for an organ transplant is constantly increasing: at the end of 2016 in the EU member countries more than 142,000 patients were waiting for a kidney, liver, heart, lung, pancreatic or intestinal transplant (source: EDQM Council of ...
ByPoietis